Valuation: NEOVACS

Market Cap 4.09K 4.58K 3.81K 3.47K 6.53K 441K 6.58K 46.03K 17.91K 225K 17.21K 16.84K 724K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -225K -187K -170K -321K -21.7M -323K -2.26M -880K -11.07M -846K -828K -35.6M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 week-17.18%
Current month-5.00%
1 month-48.65%
3 months-85.16%
6 months-96.20%
Current year-99.78%
1 week 0.18
Extreme 0.18
0.22
1 month 0.18
Extreme 0.18
0.46
Current year 0.18
Extreme 0.18
267
1 year 0.18
Extreme 0.18
4,200
3 years 0.18
Extreme 0.18
32,000,000
5 years 0.18
Extreme 0.18
351,920,000
10 years 0.18
Extreme 0.18
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 30/09/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 27/05/2003
Director/Board Member - 30/04/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
27/02/21 Sell

Chief Executive Officer

2,505,144 1.3796%
23/02/21 Sell

Chief Executive Officer

6,391,053 3.5196%
23/02/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-17.18%-99.99%-100.00% 34.02K
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.75%+78.12% 57.39B
+1.63%-1.61%+3.83%+36.89% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.41%+9.31%+58.85% 30.97B
+4.33%+8.04%+37.62%+32.27% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average +1.45%-1.84%+39.10%+105.78% 39.05B
Weighted average by Cap. +1.75%-0.41%+58.52%+137.52%

Financials

2023 2024
Net sales 533K 598K 497K 452K 852K 57.58M 858K 6M 2.34M 29.39M 2.24M 2.2M 94.47M 434K 486K 404K 368K 693K 46.85M 698K 4.88M 1.9M 23.91M 1.83M 1.79M 76.85M
Net income -8.74M -9.8M -8.15M -7.41M -13.96M -944M -14.06M -98.43M -38.29M -482M -36.79M -36M -1.55B -32.91M -36.9M -30.66M -27.91M -52.55M -3.55B -52.94M -371M -144M -1.81B -139M -136M -5.83B
Net Debt -237K -265K -220K -201K -378K -25.53M -380K -2.66M -1.04M -13.03M -995K -974K -41.89M -205K -230K -191K -174K -327K -22.14M -330K -2.31M -898K -11.3M -863K -844K -36.32M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
05/10/26 €0.1900 0.00% 42,285
02/10/26 €0.1900 0.00% 35,732
01/10/26 €0.1900 -5.00% 29,826
30/09/26 €0.2000 -4.85% 39,003
29/09/26 €0.2102 -8.37% 41,732
  1. Stock Market
  2. Stocks
  3. ALNEV Stock